Geoffrey Masuyer and Pål Stenmark will share recent research findings at the upcoming INA Toxins conference, a key international meeting for the botulinum neurotoxin field.

ToxoTech AB, a biopharmaceutical company developing therapies for neurological disorders, and AAX Biotech AB, specializing in innovative technologies for improving antibody-based medicines, today announced a strategic collaboration to advance next-generation biotherapeutics.

ToxoTech will receive tailored mentorship through the NOME programme to support strategic development and company growth.

Stockholm University researchers redesign botox

Our collaborative research identifies BoNT/A variants with improved ganglioside engagement, providing insights into how receptor interactions shape potency and selectivity.